相关实验视频
Updated: Jun 23, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
9.9K
识别可针对性的脆弱性,以规避或克服分散型大B细胞淋巴瘤中的威尼托克拉克斯抗性
Clare M Adams1, Amanda McBride1,2, Peter Michener1
1Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, 233 South 10th St., Philadelphia, PA 19107, USA.
Cancers
|June 19, 2024
概括
通过向氧化酸化或其他途径,可以克服扩散性大B细胞淋巴瘤 (DLBCL) 中的Venetoclax耐药性. 这项研究确定了治疗抗venetoclax的B细胞淋巴瘤的新策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 由于BCL2独立的生存机制,单剂venetoclax (BCL2抑制剂) 在扩散性大B细胞淋巴瘤 (DLBCL) 中具有有限的疗效.
- 了解耐药性途径对于开发针对DLBCL的有效治疗策略至关重要.
研究的目的:
- 研究DLBCL中获得的和内在的venetoclax耐药性的机制.
- 确定新的治疗点和组合策略,以克服DLBCL和其他B细胞淋巴瘤中的venetoclax耐药性.
主要方法:
- 产生和评估获得的抗venetoclax的DLBCL细胞系以及内在耐药和敏感的细胞系.
- RNA测序,药物/化合物查,以及患者样本中药物敏感性的评估.
- 抑制特定的途径,包括氧化酸化,IDH2,转录,B细胞受体信号传递和基因素脱乙酶.
主要成果:
- 在获得的与内在的venetoclax耐药性之间观察到明显的BCL2家族变化.
- 维尼托克拉克斯耐药DLBCL细胞,包括TP53突变的病例,表现出对氧化酸化的依赖.
- 抑制线粒体电子运输链复合物I和IDH2诱导的细胞死亡在抗性DLBCL中.
- 获得的和内在的耐药细胞对转录抑制剂,B细胞受体信号传递和I类组素脱乙酶敏感.
- 这些策略在DLBCL,卵泡和边缘区域淋巴瘤患者样本中显示出有效性.
结论:
- 可以针对多个途径来规避DLBCL中的各种venetoclax抵抗机制.
- 向氧化酸化,IDH2,转录,B细胞受体信号传递或基因素脱乙酶为抗venetoclax的B细胞淋巴瘤提供了潜在的治疗途径.
- 这些发现确定了B细胞恶性瘤未来临床研究的关键途径.
更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K